<DOC>
	<DOCNO>NCT02981368</DOCNO>
	<brief_summary>This study evaluate safety diagnostic performance characteristic 18F-DCFPyL Injection patient least high risk prostate cancer plan radical prostatectomy lymphadenectomy ( Cohort A ) patient locally recurrent metastatic disease willing undergo biopsy ( Cohort B ) .</brief_summary>
	<brief_title>Study 18F-DCFPyL PET/CT Imaging Patients With Prostate Cancer ( OSPREY )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate . 2 . Subjects provide sign informed consent confirm able willing comply protocol requirement . Cohort A Only : At least high risk prostate cancer define NCCN Guidelines Version 3.2016 ( clinical stage ≥T3a PSA &gt; 20 ng/mL Gleason score ≥8 ) . Scheduled planned radical prostatectomy PLND . Cohort B Only : Radiologic evidence local recurrence new progressive metastatic disease demonstrate anatomical imaging ( CT , MRI , ultrasound ) , wholebody bone scan ( 99mTcMDP Na18F ) within 4 week enrollment . If prior treatment radiation ablative therapy , evidence recurrence outside confines prior treat site ( ) need . Scheduled plan percutaneous biopsy least one amenable lesion . 1 . Subjects administer radioisotope within five physical halflives IV Xray contrast medium within 24 hour high density oral contrast medium ( oral water contrast acceptable ) within 5 day prior study drug injection . 2 . Subjects medical condition circumstance , opinion investigator , compromise obtain reliable data , achieve study objective , completion . Cohort A Only : Patients prior androgen deprivation therapy investigational neoadjuvant agent intervention Cohort B Only : Prior radiation ablative therapy intend site biopsy Initiation new therapy recurrent and/or progressive metastatic disease since radiographic documentation recurrence/progression .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diagnostic</keyword>
	<keyword>Imaging</keyword>
	<keyword>2301</keyword>
	<keyword>PET/CT</keyword>
	<keyword>PyL</keyword>
	<keyword>PSMA</keyword>
	<keyword>radical prostatectomy</keyword>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>